Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
ConditionAlopecia Areata
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19-65
SponsorNEXTGEN Bioscience
About this trial
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Eligibility criteria
Qualifiers
Men or women between ≥19 and ≤65 years of age at the time of informed consent
Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
Current episode of hair loss for ≥6 months but <8 years
Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
Disqualifiers
ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
Trial design
Treatments tested in this trial
- NXC736
- Placebo
Treatment groups
73 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov